Purple Biotech Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPBT.TA research report →
Price Chart
About the company
Purple Biotech Ltd. , a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1).
- CEO
- Gil Efron
- IPO
- 2002
- Employees
- 10
- HQ
- Rehovot, TA, IL
Get TickerSpark's AI analysis on PPBT.TA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $32.37M
- P/E
- -0.01
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.59
- EV/EBITDA
- -0.98
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -151.75%
- ROIC
- -241.86%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-219,741-254.4%
- Op Income
- $-27,458,000
- Net Income
- $-26,386,000-264.4%
- EPS
- $-0.03-34.8%
- OCF Growth
- +58.6%
- FCF Growth
- +58.6%
- 52W High
- $3.90
- 52W Low
- $0.01
- 50D MA
- $0.90
- 200D MA
- $1.03
- Beta
- -0.54
- RSI (14)
- 55
- Avg Volume
- 115.33K
No earnings-call transcripts are available for PPBT.TA yet.
- Free Float
- 93.2%
- Shares Outstanding
- 3.24B
- Float Shares
- 3.02B
Our PPBT.TA coverage
Recent articles, reports, and earnings notes.
No research on PPBT.TA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PPBT.TA report →